Ventyx Biosciences, Inc. will provide clinical and pipeline updates during its virtual investor event. Pipeline Updates: VTX3232 : The company completed a Phase 1 single- and multiple-ascending dose.
A man was deemed incompetent in November in connection with charges of shooting an Austin Police detective responding to a “check welfare” call in southeast Austin in August.
The data, published in the journal JAMA, showed patients who were obese and without diabetes experienced a 14% weight regain nearly a year after they switched to a placebo from an eight-month course of Lilly's Zepbound. Meanwhile, those who continued the treatment experienced an additional 5.5% weight reduction during the 52-week period, data from the study showed. Shares of Eli Lilly fell over 4% in morning trading.
Primary endpoint met: deucrictibant significantly reduced attack rate The primary endpoint of the CHAPTER-1 study measured the time-normalized number of investigator-confirmed HAE attacks during the treatment period. The monthly attack rate was reduced by 84.5% (p=0.0008) compared to placebo in participants who received 40 mg/day of deucrictibant. Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to place